Given careful selection of imaging targets and probes, the results generated by preclinical imaging studies can influence decisions on whether to move forward with a promising candidate, or to kill a potential drug early in the pipeline.If a drug moves into clinical development, imaging is an almost unique opportunity to follow it into humans, using the same techniques developed during the preclinical phase.
Functional and molecular small animal imaging enable a non-invasive quantification of biomarkers to answer the following questions:
All these imaging biomarkers are a unique opportunity for:
Oncodesign® has developed in-house small animal imaging skills and acquired imaging expertise by leading the Pharmimage® consortium, a pharmaco-imaging platform in Dijon (France). Pharmimage® gathers complementary skills in computer sciences, physics, electronic, chemistry, radiochemistry, biology, medicine and pharmacology to provide our clients efficient and comprehensive drug evaluation solutions.
Through Pharmimage, we are uniquely positioned to provide our clients with an integrated expertise in multi-parametric pharmaco-imaging for both preclinical and clinical applications:
The selection of the imaging modality varies with the question to be answered and the performance of the imaging device sensitivity, spatial and temporal resolution.
The main objective is to deliver new active drugs to clinicians earlier and with more accuracy by determining clinically useful biomarkers for: